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Abstract  
Background.  Evidence that passive smoking is a risk factor for cardiovascular disease and selected 
cancers is largely derived from studies in which this exposure is self-reported.  Objective 
assessment using biochemical techniques may yield a more accurate estimate of risk, although each 
approach has its strengths and weaknesses.  We examined the association of salivary cotinine, a 
widely utilized biomarker for passive smoking, and self-reported passive smoking in the home, with 
mortality from all causes, cardiovascular disease and all cancers combined. 
Methods.  In 1992, investigators on the UK Health and Lifestyle Survey collected data on salivary 
cotinine, self-reported smoking (direct and passive), and a range of covariates in 3731 men and 
women aged 25 years and over.  Mortality was ascertained using linkage to national death records.     
Results.  Analyses were based on 2523 individuals (1433 or 57% women) who classified 
themselves as non-smokers (never and former).  Seventeen years of follow-up gave rise to 588 
deaths (253 from cardiovascular disease and 146 from cancer).  In men, hazard ratios (adjusted for a 
range of covariates which included socioeconomic position, alcohol intake, and disease history) for 
the association between cotinine levels (1.3-15.0 ng/ml vs.  ≤0.3 ng/ml) and the various mortality 
outcomes were weak for total mortality (hazard ratio; 95% confidence interval:  1.22; 0.91-1.64) 
and cardiovascular disease (1.25; 0.78-1.99) and absent for all cancers combined (1.10; 0.61-2.00).  
Corresponding associations were generally stronger when self-reported passive smoking (some vs. 
none) was the exposure of interest:  1.53 (1.12-2.08), 1.88 (1.20-2.96), and 1.58 (0.85-2.93).  The 
pattern of association for women in both sets of analyses was less consistent.   
Conclusions.  In men in the present study, compared with our biochemical marker of passive 
smoking, cotinine, mortality was generally more strongly associated with self-reported passive 
smoking. 
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Introduction 
Position statements and systematic reviews conclude that passive smoking is a risk factor for 
cardiovascular disease and selected cancers.
1,2   
Most of this evidence is derived from studies using 
self-reported passive smoking.  Biochemical markers of passive smoking—carbon monoxide, 
carboxyhaemoglobin, nicotine, and cotinine—may lead to a more accurate estimate of its influence 
on health, although each method of measurement has its strengths and weaknesses.  While cotinine 
particularly appears to offer high specificity and sensitivity,
3-5 
very few studies have these data 
together with prospective measurement of health outcomes.  Moreover, to our knowledge, 
simultaneous comparison of the association of self-reported and biochemical markers with disease 
risk is rare.
6
  With data on both salivary cotinine and self-reported passive smoking, the Health and 
Lifestyle Survey provides an unusual opportunity to make such a comparison.  With passive 
smoking being relatively common – although smoking is banned in public spaces in the UK, more 
than one third of people are exposed to passive smoking in the home
7
 – quantification of its health 
impact continues to have value in informing public health policy.   
 
Methods 
The Health and Lifestyle Survey (HALS1) is a prospective cohort study of 9003 men and women 
initiated in 1984/1985.
8,9  
The target population was UK-based adults (aged 18 years and older) 
randomly selected from Electoral Registers.  In 1992, the second wave of the HALS study was 
conducted (HALS2) at which point cotinine measurements were introduced.  For the purposes of 
the present analyses therefore, HALS2 represents ‘baseline’ data collection.  Of the 6626 eligible 
HALS1 participants, 5352 (81%) were interviewed in HALS2.  Ethical approval for the HALS 
surveys was received from the British Medical Association Ethical Committee before the initiation 
of each survey.
9
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Assessment of passive smoking 
Interviews were conducted in the respondents’ home by a research worker who administered a 
questionnaire that was used to enquire about demographic characteristics, direct smoking habits, 
chronic illnesses, and socioeconomic position.
9   
The assessment of passive smoking was based on 
cotinine measurement and self-report.  All study members were asked to place a dental roll in their 
mouths for 3-5 minutes until it was saturated with saliva.  Having been stored in a specimen tube, 
the rolls were either immediately sent to the laboratory or frozen pending analyses.  Cotinine 
concentration was measured by gas-liquid chromatography.
10  
Concentrations below 0.10 ng/ml 
were undetectable and set to 0.05 ng/ml.  The present analyses are restricted to adults who self-
reported that they were former or never-smokers (current smokers were excluded).  In agreement 
with other studies,
6,11 
and based on the cotinine distribution in the present study, we created three 
cotinine groups; ≤0.3 (low exposure); 0.4-1.2 (medium); and 1.3-15.0 ng/ml (high).  Respondents 
were also asked whether they lived with someone who currently smoked.  Current non-smokers 
who answered positively were defined as self-reported passive smokers. 
 
Assessment of covariates and mortality experience 
Socioeconomic position was based on occupational social class as defined by the UK Registrar 
General’s classification.  Alcohol consumption (number of units per week) was ascertained from the 
self-reported amount of beer, cider, sherry, vermouth, wines, spirits, liqueurs, and other types of 
alcoholic drinks consumed in the previous week.  Physical activity was denoted by time spent in a 
number of leisure time activities (keeping fit, sports, jogging, swimming, cycling etc.) during the 
past fortnight.  We defined disease history as having any of the following conditions:  coronary 
heart disease, cancer, or type 2 diabetes.  
 
Using the National Health Service (NHS) Central Registry, 98% of study members were linked to 
mortality vital status.  We classified mortality according to the International Classification of 
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Diseases (ICD, 9
th
 revision) into all causes, cardiovascular disease (codes 390–460), and cancers 
from all sites combined (codes 140—209)  
 
Statistical analyses 
Having ascertained that the proportional hazards assumption had not been violated–the log-log-plot 
curves were approximately parallel–we used Cox proportional hazards regression12 with calendar 
period as time scale to estimate the relationship between passive smoking using self-report or 
cotinine and risk of death from all causes, cardiovascular disease and cancer.  Follow-up began at 
the date of the survey in 1992 and continued until date of death or June 30, 2009, whichever came 
first.   Findings from a recent meta-analysis indicate that direct cigarette smoking was associated 
with a greater risk of coronary heart disease in women than men.
13
  On the basis that the same 
observation might be made when passive smoking was the exposure of interest, men and women 
were analyzed separately.   
 
Results 
Out of 5352 participants in HALS2, 3731 (70%) had complete data (mean age 51.0 years; 2083 
were female).  Of these, 1321 (35.4 %) study members reported that they were never smokers, 1328 
(35.6 %) former smokers, and 1028 (29.0 %) current smokers.  The corresponding geometric means 
(IQR) for cotinine (ng/ml) were 0.69 (0.30-1.73), 0.95 (0.40-2.00), and 218.57 (191.15-423.68) in 
women; and 0.96 (0.40-2.30), 1.33 (0.50-3.20), and 279.05 (227.85-471.58) in men.  Thus, while 
cotinine levels were similar in never and former smokers, they were markedly higher in current 
smokers. 
 
Follow-up time among the 3731 full sample was 17.1 years (57,364 person-years), giving rise to 
886 deaths from all causes, of which 359 were from cardiovascular disease and 245 from cancers.  
As anticipated, in women, self-reported current smokers relative to never-smokers experienced 
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markedly elevated rates of total (age-adjusted hazard ratio [HR]; 95% confidence interval [CI]:  
2.45; 1.91-3.14), cardiovascular disease (2.27; 1.52-3.40), and cancer (2.78; 1.81-4.29) mortality.  
Corresponding results (95 % CI) for men were: 2.28 (1.70-3.06), 1.86 (1.16-2.99) and 3.39 (1.86-
6.17).    
 
The primary analytical sample was a combined group of 2582 never smokers or former smokers, 
the latter group not having smoked for one year or more.  Using previously utilised thresholds,
14-15
 
the 59 participants who reported that they were non-smokers but nonetheless had cotinine levels at 
or above 15 ng/ml were excluded as they were regarded as current smokers.  This resulted in an 
analytical sample of 2523 non-smokers (1314  never smokers, 1209 former smokers).  During 
follow-up, 588 people died (253 from cardiovascular disease, 146 from all cancers combined).  In 
Table 1 we show the associations between salivary cotinine level and the three mortality outcomes 
in these non-smoking study participants stratified by gender.  There was some evidence of an age-
adjusted elevated risk of total (men only) and cardiovascular disease mortality (men and women) in 
the highest cotinine group, although statistical significance at conventional levels was not evident in 
any of these analyses.  Adjustment for a range of additional potential confounders (socioeconomic 
position, alcohol intake, physical activity, and disease history) did not appreciably change these 
effect estimates.   
 
Next, in the same group of non-smokers, we examined the association between self-reported 
passive smoking and mortality experience (Table 2).  Using this method, passive smoking was 
reported by 179 (16.4 %) never- or former smoking men and by 276 (19.3 %) never- or former 
smoking women.  As expected, cotinine levels (geometric means [IQR]) in women who reported 
passive exposure to cigarette smoke were higher (1.90 [1.10-4.00]) than those who did not report 
living with a smoker (0.56 [0.30-1.30], p-value for difference<0.001).  Corresponding values in 
men were 3.24 (1.80-5.90) and 0.76 (0.40-1.80) (p-value for difference<0.001).  In men, self- 
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Table 1. Hazard ratios (95% confidence intervals) for the relation of salivary cotinine (ng/ml) with cause-specific mortality risk among non-
smoking men and women: the UK Health and Lifestyle Survey 2 (N=2523) 
 
 All-cause mortality  Cardiovascular disease  mortality  All cancer mortality 
 No. of 
deaths/no. at 
risk 
Age-adjusted Fully- 
adjusted
1
 
 No. of 
deaths/no. at 
risk 
Age-
adjusted 
Fully- 
adjusted
1
 
 No. of 
deaths/no. 
at risk 
Age-
adjusted 
Fully- 
adjusted
1
 
            
Men (N=1090)            
≤0.3 ng/ml 85/220 1 (ref) 1  34/220 1 1  21/220 1 1 
0.4-1.2  90/387 1.02  
(0.76-1.38) 
1.01 
(0.75-1.36) 
 39/387 1.12  
(0.71-1.79) 
1.06 
(0.66-1.69) 
 22/387 0.93  
(0.51-1.70) 
0.95 
(0.52-1.75) 
1.3-15.0 125/483 1.26  
(0.95-1.67) 
1.22 
(0.91-1.64) 
 51/483 1.31  
(0.84-2.05) 
1.25 
(0.78-1.99) 
 29/483 1.08  
(0.61-1.92) 
1.10 
(0.61-2.00) 
P for trend
2
  0.091 0.165   0.223 0.336   0.760 0.723 
          
Women (N=1433)          
≤0.3 ng/ml 89/391 1 1  35/391 1 1  28/391 1 1 
0.4-1.2 102/546 0.89  
(0.67-1.18) 
0.81  
(0.61-1.09) 
 43/546 0.96  
(0.62-1.50) 
0.82 
(0.52-1.30) 
 25/546 0.67  
(0.39-1.15) 
0.66 
(0.38-1.14) 
1.3-15.0 97/496 0.99  
(0.75-1.33) 
0.90 
(0.67-1.22) 
 51/496 1.37  
(0.89-2.12) 
1.19 
(0.76-1.87) 
 21/496 0.64  
(0.36-1.13) 
0.63 
(0.35-1.13) 
P-value for trend
2
  0.987 0.544   0.127 0.347   0.117 0.114 
            
 
1
Full adjustment is adjustment for:  baseline age, socioeconomic position, alcohol intake, physical activity and a history of heart disease, cancer and diabetes.    
2
From Cox regression models of the linear associations between three categories of cotinine level and mortality in non-smokers.    
 8 
 
Table 2. Hazards ratios (95% confidence intervals) for the relation of self-reported passive smoking with cause-specific mortality risk among 
non-smoking men and women: the UK Health and Lifestyle Survey 2 (N=2523) 
 
 
 All-cause mortality   Cardiovascular disease mortality   All cancer mortality 
 No. of 
deaths/no. at 
risk 
Age-adjusted Fully- 
adjusted
1
 
 No. of 
deaths/no. at 
risk 
Age-adjusted Fully- 
adjusted
1
 
 No. of 
deaths/no. at 
risk 
Age-adjusted Fully- 
adjusted
1
 
Men (N=1090)            
Non passive smokers 247/911 1 (ref) 1  98/911 1 1   59/911 1 1 
Passive smokers 53/179 1.62  
(1.20-2.19) 
1.53 
(1.12-2.08) 
 26/179 2.03 
(1.31-3.15) 
1.88 
(1.20-2.96) 
 13/179 1.58 
(0.86-2.90) 
1.58 
(0.85-2.93) 
P-value for difference  0.002 0.007   0.002 0.006   0.143 0.150 
            
Women (N=1433)            
Non passive smokers 255/1157 1 1  110/1157 1 1  66/1157 1 1 
Passive smokers 33/276 0.99 
(0.68-1.43) 
0.96 
(0.66-1.39) 
 19/276 1.58 
(0.96-2.60) 
1.55 
(0.94-2.56) 
 8/276 0.72 
(0.34-1.51) 
0.72 
(0.34-1.51) 
P-value for difference  0.939 0.837   0.072 0.085   0.385 0.381 
            
 
1
Fully adjustment is adjustment for:  baseline age, socioeconomic position, alcohol intake, physical activity and a history of heart disease, cancer and diabetes 
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reported passive smoking was associated with elevated rates of all three mortality endpoints to 
differing degrees of statistical significance.  For women, only cardiovascular disease  mortality rates 
were raised among passive smokers; again, statistical significance was not apparent.  This pattern of 
association remained after multivariable adjustment.  
 
In sensitivity analyses, additional adjustment for smoking history (never and former smoking), 
educational level, marital status, body mass index, and systolic blood pressure had no marked 
impact on the effect estimates.  We also conducted some subgroup analyses.  To address the 
problem that individuals who report being former smokers may oscillate between cessation and re-
initiation,
16
 and to facilitate comparison with some studies where the focus has been never-smokers,
 
14,17-19
  we repeated analyses in never-smokers only.  Numbers were markedly lower in this group 
(N=1314; 218 deaths during follow-up) leading to lower statistical stability.  The associations 
between cotinine level and mortality outcomes were generally of the same magnitude as in the 
afore-described analyses except for cardiovascular disease-mortality among women, which was 
more strongly associated with cotinine level among never smokers than among all non-smokers 
(tables available upon request).    
 
Discussion 
Our main findings were that cotinine level, our biomarker of passive smoking, was weakly related 
to mortality among non-smokers in the present cohort study.  In contrast, when the exposure was 
derived from self-report, the passive smoking—mortality relationship was stronger and more 
consistent, most notably among men.   Investigators utilising subjective measures of passive 
smoking status have found an increased risk of mortality, with hazard ratios typically ranging from 
1.1 to 1.7, although this varies according to cause of death, age, sex, and type and intensity of 
passive smoking.
17-20
  Our results for self-reported passive smoking and mortality from all-causes, 
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cardiovascular disease  and cancer broadly fall within this range, particularly in analyses of men.  
That we did not find evidence of an association between cotinine and cardiovascular disease  
mortality is not unique.
6,21
 
 
Self-reported passive smoking may be an overall measure of habitual exposure, although, in this 
study, only in one domain – the home – with participants not asked about exposure in the workplace 
or elsewhere.   By contrast, while cotinine may capture exposure in all contexts, it has a half-life of 
20 hours so will only index passive smoking exposure in the very recent past.  It is also the case that 
there is some individual variability in nicotine metabolism and elimination.
4,5
     
 
HALS2 has a series of strengths.  The participants in HALS2 were compared with those of the 1991 
census, and the distribution of the HALS2 population by age and region was similar to that seen in 
the 1991 census.  This suggests a reasonable degree of generalizability of our results.  Further, in a 
prior comparison of baseline risk factor–mortality associations, in people who participated in the 
resurvey and those who did not, effect estimates were similar indicating that selection bias at least 
based on the baseline sample had not occured.
22   
Moreover, known risk factor– cardiovascular 
disease  associations (for obesity, raised blood pressure, amongst others) are also evident in 
HALS,
22
 as were the usual effects for direct smoking reported herein.  This gives us some 
confidence in the more novel results for passive smoking reported herein.   
 
Our study is of course not without its shortcomings.  The self-report passive smoking variable was 
dichotomous and as such we could not examine dose-response relationships with the mortality 
outcomes.  Passive smoking, together with other exposure and covariate data, was captured on a 
single (baseline) occasion which may have resulted in some degree of misclassification as these 
variables will have changed during follow-up.  However, a high proportion of the HALS 
participants had stable smoking habits over the seven years between surveys, with 88.2 % of never-
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smoking men and 84.1 % of never-smoking women in HALS1 being so classified in HALS2. 
Similarly high stability was apparent for former and current smokers (results not shown).  Finally, 
while recognizing that because direct smoking is not linked to every cancer phenotype there is no 
good reason to expect passive smoking to be, low numbers nonetheless meant we had to utilise all 
cancers combined as a single outcome.   
 
In conclusion, in the present study, mortality outcomes were generally more strongly associated 
with self-reported passive smoking than salivary cotinine.     
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What is already known on this subject? 
 Evidence for the deleterious health impact of passive smoking is accumulating.   
 With these data almost exclusively based on self-assessed passive smoking, we report on rare 
analyses of the relation of cotinine, a biomarker of passive smoking, with mortality risk.  
 
What does this study add? 
 In men, we found stronger effects for mortality in relation to self-reported passive smoking 
compared with salivary cotinine.   
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